GENERAL2 Oct 2026
Cipla on Maharashtra FDA action: ‘Disappointing’, says Pune warehouse follows protocols - CNBC TV18
Maharashtra FDA (Food and Drug Administration) has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences' Pune warehouse. The action follows findings on Reactin Plus packaging, storage and record-keeping. Cipla called the decision disappointing and said the facility follows required protocols. If you sell or stock medicines, check that your licences, storage records and packaging details are in order before an inspection.
Key Statutory Highlights
- Maharashtra FDA has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences' Pune warehouse.
- The action was linked to findings on Reactin Plus packaging, storage and record-keeping at the facility.
- Cipla called the decision disappointing and said the warehouse complies with the required protocols.
Actionable Advice for Taxpayers / Founders:Review your own drug licences, storage conditions and record-keeping, and consider getting a compliance check done so you are ready if an inspector visits.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: